

10/ 750,326

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 4 APR 04 STN AnaVist \$500 visualization usage credit offered
NEWS 5 MAY 10 CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS 6 MAY 11 KOREAPAT updates resume
NEWS 7 MAY 19 Derwent World Patents Index to be reloaded and enhanced
NEWS 8 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAPLUS and
USPATFULL/USPAT2
NEWS 9 MAY 30 The F-Term thesaurus is now available in CA/CAPLUS
NEWS 10 JUN 02 The first reclassification of IPC codes now complete in
INPADOC
NEWS 11 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and
and display fields
NEWS 12 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 13 JUL 07 Coverage of Research Disclosure reinstated in DWPI

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:41:14 ON 10 JUL 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 15:41:23 ON 10 JUL 2006

10/ 750,326

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 9 JUL 2006 HIGHEST RN 891170-23-3
DICTIONARY FILE UPDATES: 9 JUL 2006 HIGHEST RN 891170-23-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10750326.str



chain nodes :

11 12 13 14 15 18 19 20 21 22

ring nodes :

1 2 3 4 5 6 7 8 9 10

chain bonds :

7-11 8-13 9-12 10-18 13-14 14-15 18-19 20-21 20-22

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 7-11 8-9 8-13 9-10 9-12 10-18
18-19 20-21 20-22

exact bonds :

13-14 14-15

10/ 750,326

G1:OH,COOH,NH2,Cb, [*1]

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 18:CLASS 19:CLASS 20:CLASS
21:CLASS 22:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 OH,COOH,NH2,Cb,[@1]

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sample

SAMPLE SEARCH INITIATED 15:41:50 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 182 TO ITERATE

100.0% PROCESSED 182 ITERATIONS

4 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 2831 TO 4449


PROJECTED ANSWERS: 4 TO 200

L2 4 SEA SSS SAM L1

=> d scan l2

10/ 750,326

L2 4 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 3(2H)-Quinazolineacetic acid, 1-[(4-bromo-2-fluorophenyl)methyl]-1,4-
dihydro-6,7-dimethoxy-2,4-dioxo- (9CI)
MF C19 H16 Br F N2 O6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

10/ 750,326

=> s l1 ful

FULL SEARCH INITIATED 15:42:12 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 4349 TO ITERATE

100.0% PROCESSED 4349 ITERATIONS

122 ANSWERS

SEARCH TIME: 00.00.01

L3 122 SEA SSS FUL L1

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

167.38

167.59

FILE 'HCAPLUS' ENTERED AT 15:42:19 ON 10 JUL 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Jul 2006 VOL 145 ISS 3

FILE LAST UPDATED: 9 Jul 2006 (20060709/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 14 L3

=> d his

(FILE 'HOME' ENTERED AT 15:41:14 ON 10 JUL 2006)

FILE 'REGISTRY' ENTERED AT 15:41:23 ON 10 JUL 2006

L1 STRUCTURE UPLOADED

L2 4 S L1 SAMPLE

L3 122 S L1 FUL

FILE 'HCAPLUS' ENTERED AT 15:42:19 ON 10 JUL 2006

L4 14 S L3

=> d l4 1- ibib abs hitstr

YOU HAVE REQUESTED DATA FROM 14 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:566933 HCAPLUS

DOCUMENT NUMBER: 141:270985

TITLE: Three-Dimensional Quantitative Structure-Activity Relationship Analysis of a Set of Plasmodium falciparum Dihydrofolate Reductase Inhibitors Using a Pharmacophore Generation Approach

AUTHOR(S): Parenti, Marco Daniele; Pacchioni, Sara; Ferrari, Anna Maria; Rastelli, Giulio

CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Università di Modena e Reggio Emilia, Modena, 41100, Italy

SOURCE: Journal of Medicinal Chemistry (2004), 47(17), 4258-4267

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A 3D pharmacophore model able to quant. predict inhibition constns. was derived for a series of inhibitors of Plasmodium falciparum dihydrofolate reductase (PfDHFR), a validated target for antimalarial therapy. The data set included 52 inhibitors, with 23 of these comprising the training set and 29 an external test set. The activity range, expressed as K_i of the training set mols. was from 0.3 to 11 300 nM. The 3D pharmacophore, generated with the HypoGen module of Catalyst 4.7, consisted of two hydrogen bond donors, one pos. ionizable feature, one hydrophobic aliphatic feature, and one hydrophobic aromatic feature and provided a 3D-QSAR model with a correlation coefficient of 0.954. Importantly, the type and spatial location of the chemical features encoded in the pharmacophore were in full agreement with the key binding interactions of PfDHFR inhibitors as previously established by mol. modeling and crystallog. of enzyme-inhibitor complexes. The model was validated using several techniques, namely, Fisher's randomization test using CatScramble, leave-one-out test to ensure that the QSAR model is not strictly dependent on one particular compound of the training set, and activity prediction in an external test set of compds. In addition, the pharmacophore was able to correctly classify as active and inactive the dihydrofolate reductase and aldose reductase inhibitors extracted from the MDDR database, resp. This

test was performed to challenge the predictive ability of the pharmacophore with two classes of inhibitors that target very different binding sites. Mol. diversity of the data sets was finally estimated by the Tanimoto approach. The results obtained provide confidence for the utility of the pharmacophore in the virtual screening of libraries and databases of compds. to discover novel PfDHFR inhibitors.

IT 133166-46-8 133166-55-9 133166-60-6

136148-02-2 180632-11-5 180632-13-7

180632-19-3 180632-21-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL


(Biological study); USES (Uses)

(QSAR of Plasmodium falciparum dihydrofolate reductase inhibitors using pharmacophore generation approach)

RN 133166-46-8 HCAPLUS


CN 3(2H)-Quinazolineacetic acid, 6-bromo-1-[(4-bromo-2-fluorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 133166-55-9 HCAPLUS


CN 3(2H)-Quinazolineacetic acid, 1-[(4-bromo-2-fluorophenyl)methyl]-1,4-dihydro-6-iodo-2,4-dioxo- (9CI) (CA INDEX NAME)



RN 133166-60-6 HCAPLUS


CN 3(2H)-Quinazolineacetic acid, 1-[(3,4-dichlorophenyl)methyl]-1,4-dihydro-6-methyl-2,4-dioxo- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 136148-02-2 HCAPLUS


CN 3(2H)-Quinazolineacetic acid, 1-[(3,4-dichlorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)



RN 180632-11-5 HCAPLUS


CN 3(2H)-Quinazolineacetic acid, 1-[[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 180632-13-7 HCAPLUS


CN 3(2H)-Quinazolineacetic acid, 1-[[3-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 180632-19-3 HCAPLUS

CN 3(2H)-Quinazolineacetic acid, 1-[[4-[[[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]sulfonyl]amino]phenyl]methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



RN 180632-21-7 HCAPLUS
 CN 3((2H)-Quinazolin-2-ylidene)acetic acid, 1-([3-([4-((2,4-dioxo-5-thiazolidinyl)methyl)phenyl)sulfonyl]amino)phenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2004:428823 HCAPLUS
 DOCUMENT NUMBER: 140:417984
 TITLE: Remedies for vertebral canal stenosis
 INVENTOR(S): Takenobu, Yoshifumi; Kamanaka, Yoshihisa; Obata, Takaki; Ito, Hidenori
 PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 58 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004/03491	A1	20040527	WO 2003-JP14454	20031113
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KH, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG AU 2003280767 A1 20040603 AU 2003-280767 20031113 US 2006058310 A1 20060316 US 2005-534051 20050505 PRIORITY APPLN. INFO.: JP 2002-330425 A 20021114 WO 2003-JP14454 W 20031113				

OTHER SOURCE(S): MARPAT 140:417984
 AB A preventive and/or a remedy for vertebral canal stenosis contains an aldose reductase inhibitory compound, such as 5-(2-propenylidene)-4-oxo-2-thioxo-3-thiazolidineacetic acid derivative. The above remedy is efficacious in preventing and/or treating vertebral canal stenosis, such as lumbar vertebral canal stenosis. Administration of epalrestat, AS-3201, and fildarestat improved walking dysfunction in the rat spinal stenosis model. Tablets were formulated containing epalrestat 50, Ca CMC 2, Mg stearate 1, and microcryst. cellulose 47 mg per tablet.
 IT 136148-02-2
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (aldose reductase inhibitors as remedies for vertebral canal stenosis symptoms)
 RN 136148-02-2 HCAPLUS
 CN 3((2H)-Quinazolin-2-ylidene)acetic acid, 1-([3,4-dichlorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:502764 HCAPLUS
 DOCUMENT NUMBER: 137:63251
 TITLE: Solid phase and combinatorial library syntheses of fused 2,4-pyrimidinediones
 INVENTOR(S): Gordeev, Mikhail F.; Patel, Dinesh V.
 PATENT ASSIGNEE(S): Versicor, Inc., USA
 SOURCE: U.S., 22 pp., Cont.-in-part of U.S. 6,025,371.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6413724	B1	20020702	US 1997-795189	19970204
US 6025371	A	20000215	US 1996-740103	19961028
WO 9818781	A2	19980507	WO 1997-US19483	19971027

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LU, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
 AU 9869083 A1 19980522 AU 1998-69083 19971027
 US 1996-740103 A2 19961028
 US 1997-795189 A 19970204
 US 1997-816120 A2 19970311
 WO 1997-US19483 W 19971027

PRIORITY APPLN. INFO.:
 AU 9869083 A1 19980522 AU 1998-69083 19971027
 US 1996-740103 A2 19961028
 US 1997-795189 A 19970204
 US 1997-816120 A2 19970311
 WO 1997-US19483 W 19971027


OTHER SOURCE(S): MARPAT 137:63251
 AB A combinatorial library comprising PR [P = quinazolinidionyl, pyrimidopyrimidinidionyl, pyridopyrimidinidionyl, pteridinedionyl, R = (CH₂)_mCHR₇(CH₂)_nCHR₈YCHR₉(CH₂)_pQ, (CH₂)_mCHR₇(CH₂)_nQ, etc., R₇, R₈, R₉ = H, alkyl, aryl, OH, amino, SH, SR₁₀, O, COR, amino acid sidechain; Y = alkyl, aryl, O, amino; X = CO₂, CO, S, O, amino, CONHO, CONR₁₀; R₁₀ = alkyl, aryl, heteroaryl; m, n, o, p = 0-4; Q = solid support], is claimed. Thus, Fmoc-Ala-Sasrin resin was deprotected by agitation with 20% piperidine in DMF. Fmoc-Phe-OH, 1-hydroxybenzotriazole, and diisopropylcarbodiimide were mixed in N-methylpyrrolidin-2-one, and the mixture stirred at r. t. for 20 min. The resultant solution was added to the above deprotected H-Ala-Sasrin, and the mixture shaken for 1.5 h. The Fmoc-Phe-Ala-Sasrin resin thus obtained was deprotected by agitation with 20% piperidine in DMF at r. t. and dried under vacuum; 2-MeOC₆H₄NO in pyridine/DMF was added to the deprotected dipeptide amine resin and the mixture agitated for 1 h. The resultant urea resin was filtered, dried, and cyclized by stirring at 60° with 5% tetramethylguanidine or 5% 1,8-diazabicyclo[5.4.0]undec-7-ene in N-methylpyrrolidin-2-one for 21 h. The resultant quinazolinodione resin was cleaved with 3% CF₃CO₂H in CH₂Cl₂ to give 3-[(5S)-1-benzyl-1-(S)-2-carboxylaminopropionic acid]methyl-2,4-(1H,3H)-quinazolinodione.
 IT 188789-64-2P 188789-65-3P 207346-35-8P
 207346-37-0P 207346-39-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 207346-37-0 HCAPLUS
 CN 3(2H)-Quinazolinacetic acid, 1,4-dihydro-1-(2-naphthalenylmethyl)-2,4-dioxo- α -(phenylmethyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 207346-39-2 HCAPLUS
 CN 3(2H)-Quinazolinacetic acid, 1-[(2-cyanophenyl)methyl]-1,4-dihydro-2,4-dioxo- α -(phenylmethyl)-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (solid phase and combinatorial library syntheses of fused 2,4-pyrimidinediones)
 RN 188789-64-2 HCAPLUS
 CN 3(2H)-Quinazolinacetic acid, 1,4-dihydro-1-[(4-methoxyphenyl)methyl]-2,4-dioxo- α -(phenylmethyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 188789-65-3 HCAPLUS
 CN 3(2H)-Quinazolinacetic acid, 1-(2-amino-2-oxoethyl)-1,4-dihydro-2,4-dioxo- α -(phenylmethyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 207346-35-8 HCAPLUS
 CN 3(2H)-Quinazolinacetic acid, 1,4-dihydro-2,4-dioxo- α ,1-bis(phenylmethyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1999:7976 HCAPLUS
 DOCUMENT NUMBER: 130:52432
 TITLE: Method for producing quinazolinodiones and quinazolinodione libraries in solid phase
 INVENTOR(S): Puhl, Michael; Adida, Serge; Klinge, Dagmar; Kling, Andreas
 PATENT ASSIGNEE(S): BASF A.-G., Germany
 SOURCE: PCT Int. Appl., 45 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9856770	A1	19981217	WO 1998-EP3226	19980529

W: AL, AU, BG, BR, BY, CA, CN, CZ, GE, HU, ID, IL, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TH
 RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
 DE 19724983 A1 19981217 DE 1997-19724983 19970613
 CA 2294175 AA 19981217 CA 1998-2294175 19980529
 AU 9881084 A1 19981230 AU 1998-81084 19980529
 EP 988291 A1 20000329 EP 1998-930763 19980529
 R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE, IE, FI
 JP 2002507199 T2 20020305 JP 1999-501455 19980529
 ZA 9805122 A 19991213 ZA 1998-5122 19980612
 DE 1997-19724983 A 19970613
 WO 1998-EP3226 W 19980529


PRIORITY APPLN. INFO.:
 WO 1998-EP3226 W 19980529

OTHER SOURCE(S): MARPAT 130:52432
 GI



AB Quinazolinodione I [P = solid-phase support; A = O, NH; R₁, R₂ = H, (un)substituted alkyl, cycloalkyl, aryl, heteroaryl; R₁R₂ = 3-8-membered ring; R₃, R₄ = H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, halogen, (un)substituted NH₂, OH, SH, CO₂H, CONH₂, NO₂, CN; R₃R₄ = atoms required to form an aromatic or heteroarom. ring; R₅ = (un)substituted alkyl, aralkyl.
 heteroaralkyl; m, n = 0-6] were prepared by treating a polymer-bound amino acid H₂N(CH₂)_mCR₁R₂(CH₂)_nCOAP with a 2-aminobenzoic acid or isatoic anhydride to give the amide, treating this with a heterocyclic carbonyl compound, and alkylating. The process is suitable for producing libraries of I for high-throughput screening.
 IT 217457-83-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)

L4 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 (prepn. of quinazolinones and quinazolinone libraries in solid phase)
 RN 217457-83-5 HCAPLUS
 CN 3(2H)-Quinazolinacetic acid, 1,4-dihydro- α -(2-methylpropyl)-2,4-dioxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1998:543060 HCAPLUS
 DOCUMENT NUMBER: 129:161566
 TITLE: Solid phase and combinatorial library syntheses of 3,1-benzoxazin-4-ones.
 INVENTOR(S): Gordeev, Mikhail; Patel, Dinesh
 PATENT ASSIGNEE(S): Versicor, Inc., USA
 SOURCE: PCT Int. Appl., 38 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9833783	A1	19980806	WO 1998-US2064	19980204
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GI, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9862648	A1	19980825	AU 1998-62648	19980204
PRIORITY APPLN. INFO.:			US 1997-795191	A2 19970204
			WO 1998-US2064	W 19980204


AB A combinatorial library containing derivs. of 3,1-benzoxazine-4-one is claimed. The invention further provides methods for the identification of bioactive, 3,1-benzoxazine-4-ones from those libraries. Thus, Fmoc-protected sarcosine on Tentagel resin was deprotected with piperidine in DMF followed by agitation with 2-(p-nitrophenyl)carbamoyl-4,5-difluorobenzoate in pyridine/DMF. The product was agitated with N-methylpiperazine in N-methylpyrrolidone followed by ester deprotection with KOTf in THF and cyclization using p-toluenesulfonyl chloride, and resin cleavage with CF₃CO₂H to give 2-(N-midomethyl-N-methyl)amino-6-fluoro-7-(4-methyl)piperazino-3,1-benzoxazin-4-one.

IT 207346-35-8P
 RL: SPN (Synthetic preparation); PREP (Preparation) (solid phase and combinatorial library syntheses of 3,1-benzoxazin-4-ones)

RN 207346-35-8 HCAPLUS
 CN 3(2H)-Quinazolinacetic acid, 1,4-dihydro-2,4-dioxo- α ,1-bis(phenylmethyl)-, (eS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1998:293492 HCAPLUS
 DOCUMENT NUMBER: 129:4654
 TITLE: Preparation of fused 2,4-pyrimidinone combinatorial libraries having antimicrobial and β -lactamase activity.
 INVENTOR(S): Gordeev, Mikhail; Patel, Dinesh
 PATENT ASSIGNEE(S): Versicor, Inc., USA
 SOURCE: PCT Int. Appl., 71 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9818781	A2	19980507	WO 1997-US19483	19971027
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 6025371	A	20000215	US 1996-740103	19961028
US 6413724	B1	20020702	US 1997-795189	19970204
US 9869083	A1	19980522	AU 1998-69083	19971027
PRIORITY APPLN. INFO.:			US 1996-740103	A 19961028
			US 1997-795189	A 19970204
			US 1997-816120	A2 19970311
			WO 1997-US19483	W 19971027

AB Combinatorial libraries comprising pyrimidopyrimidinones, 2,4-pteridinediones, pyrimidopyridazinones, and azolopyrimidinones substituted at the 3 position by substituted alkyl chains are claimed. A library of quinazoline-2,4-diones was prep'd; several inhibited β -lactamase with IC₅₀ = 1.3-183 μ M.


IT 207346-51-8 207346-52-9 207346-53-0
 207346-55-2 207346-61-0 207346-63-2
 207346-65-4 207346-66-5 207346-67-6
 207346-68-7 207346-69-8 207346-71-2
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preparation of fused 2,4-pyrimidinone combinatorial libraries having antimicrobial and β -lactamase activity)

RN 207346-51-8 HCAPLUS
 CN 3(2H)-Quinazolinacetic acid, 1-([1,1'-biphenyl]-4-ylmethyl)-6-chloro-1,4-dihydro-2,4-dioxo- α -(phenylmethyl)-, (eS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/ 750,326

L4 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 207346-52-9 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-([1,1'-biphenyl]-4-ylmethyl)-6-chloro-1,4-dihydro-α-(2-methylpropyl)-2,4-dioxo-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 207346-53-0 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-([1,1'-biphenyl]-4-ylmethyl)-1,4-dihydro-5-nitro-2,4-dioxo-α-(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 207346-55-2 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-([1,1'-biphenyl]-4-ylmethyl)-6-chloro-α-(cyclohexylmethyl)-1,4-dihydro-2,4-dioxo-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 207346-61-0 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1,4-dihydro-5-nitro-2,4-dioxo-1-[(4-(phenylmethoxy)phenyl)methyl]-α-(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 207346-63-2 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-([1,1'-biphenyl]-4-ylmethyl)-1,4-dihydro-7-(methoxycarbonyl)-2,4-dioxo-α-(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 207346-65-4 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 6-chloro-1,4-dihydro-2,4-dioxo-1-[(4-(phenylmethoxy)phenyl)methyl]-α-(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 207346-66-5 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[(9,10-dihydro-9,10-dioxo-2-anthracenyl)methyl]-1,4-dihydro-5-nitro-2,4-dioxo-α-(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 207346-67-6 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-([1,1'-biphenyl]-4-ylmethyl)-6-chloro-1,4-dihydro-α-methyl-2,4-dioxo-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 207346-68-7 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 6-chloro-1-[(9,10-dihydro-9,10-dioxo-2-anthracenyl)methyl]-1,4-dihydro-2,4-dioxo-α-(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 207346-69-8 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-([1,1'-biphenyl]-4-ylmethyl)-7-fluoro-1,4-dihydro-2,4-dioxo-α-(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 207346-71-2 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-([1,1'-biphenyl]-4-ylmethyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-2,4-dioxo-α-(phenylmethyl)-, (αS)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 207346-70-1
CMF C35 H34 N4 O4

Absolute stereochemistry.




CH 2

CRN 76-05-1
CMF C2 H F3 O2




IT 188789-64-2P 188789-65-3P 207346-35-8P
207346-37-0P 207346-39-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of fused 2,4-pyrimidinone combinatorial libraries having antimicrobial and β-lactamase activity)
RN 188789-64-2 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[(4-methoxyphenyl)methyl]-2,4-dioxo-α-(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 188789-65-3 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-(2-amino-2-oxoethyl)-1,4-dihydro-2,4-dioxo-α-(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 207346-35-8 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1,4-dihydro-2,4-dioxo-α,1-bis(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 207346-37-0 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1,4-dihydro-1-(2-naphthalenylmethyl)-2,4-dioxo-α-(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 207346-39-2 HCAPLUS

CN 3(2H)-Quinazolineacetic acid, 1-[(2-cyanophenyl)methyl]-1,4-dihydro-2,4-dioxo-α-(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1997:187295 HCAPLUS
 DOCUMENT NUMBER: 126:264072
 TITLE: A general and efficient solid phase synthesis of quinazoline-2,4-diones
 AUTHOR(S): Gordeev, Mikhail F.; Hui, Hon C.; Gordon, Eric M.; Patel, Dinesh V.
 CORPORATE SOURCE: Versicor, Inc., South San Francisco, CA, 94080, USA
 SOURCE: Tetrahedron Letters (1997), 38(10), 1729-1732
 CODEN: TELEAY; ISSN: 0040-4039
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 126:264072

AB An efficient solid phase synthesis of chiral quinazolinones is described. Immobilized amino acid based urea derivs. undergo a racemization-free heterocyclization upon gentle heating in presence of tetramethylguanidine to afford fused pyrimidine-2,4-diones, which are smoothly Ni-alkylated under mild conditions to produce immobilized quinazolinones. The method is amenable to combinatorial synthesis and offers broad scope for structural and chemical diversity, as illustrated by prepared of a fused thieno[2,3-d]pyrimidine-2,4-dione and a hydroxamate pharmacophore bearing a quinazolinone derivative
 IT 188789-64-2P 188789-65-3P 188789-66-4P
 188789-67-5P 188789-68-6P 188789-69-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (solid phase synthesis of quinazoline-2,4-diones)
 RN 188789-64-2 HCAPLUS
 CN 3(2H)-Quinazolinoneacetic acid, 1,4-dihydro-1-[(4-methoxyphenyl)methyl]-2,4-dioxo- α -(phenylmethyl)-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 188789-65-3 HCAPLUS
 CN 3(2H)-Quinazolinoneacetic acid, 1-(2-amino-2-oxoethyl)-1,4-dihydro-2,4-dioxo- α -(phenylmethyl)-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 Absolute stereochemistry.




RN 188789-69-7 HCAPLUS
 CN 3(2H)-Quinazolinoneacetic acid, 6-chloro-1,4-dihydro-1-(3-hydroxypropyl)-2,4-dioxo- α -(phenylmethyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 188789-66-4 HCAPLUS
 CN 1,3(2H,4H)-Quinazolinoneacetic acid, 2,4-dioxo- α -(phenylmethyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 188789-67-5 HCAPLUS
 CN 3(2H)-Quinazolinoneacetic acid, 6-chloro-1-(cyclopropylmethyl)-1,4-dihydro-2,4-dioxo- α -(phenylmethyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 188789-68-6 HCAPLUS
 CN 3(2H)-Quinazolinoneacetic acid, 6-chloro-1-[(2-cyanophenyl)methyl]-1,4-dihydro-2,4-dioxo- α -(phenylmethyl)-, (S)- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1996:537366 HCAPLUS
 DOCUMENT NUMBER: 125:195674
 TITLE: Preparation of 2,4-dioxo-1,2,3,4-tetrahydroquinazoline derivatives having blood sugar-lowering and aldose reductase-inhibiting activity
 INVENTOR(S): Myasaka, Shozo; Sato, Hiroko; Matsushima, Hiroaki; Sugizaki, Myoshi
 PATENT ASSIGNEE(S): Terumo Corp, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 33 pp.
 CODEN: JKOKAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08143566	A2	19960604	JP 1994-291053	19941125
PRIORITY APPLN. INFO.:			JP 1994-291053	19941125
OTHER SOURCE(S):			MARPAT 125:195674	
GI				


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I], R3, R4 = H, halo, lower alkyl, lower alkoxy, haloalkyl; R1, R2 = R5-CO2R6, CH2CGH4-A-T, (CH2)m-B-T; wherein R5 = Cl-3 alkyls; R6 = H, Cl-8 alkyl; A = CH2, 1,2-, 1,3-, or 1,4-NHSO2CGH4CH2, -CH2CH2CGH4CH2, or -CH2CH2CGH4CH2; T = heterocyclyl having weakly acidic H; m = 1-7; B = NHSO2-CGH4-CH2, which are useful for the treatment of diabetes complications such as cataract, retinopathy, or nerve or kidney disorders, are prepared. Thus, Et 2,4-dioxo-2H-3,1-benzoxazine-1(4H)-acetate, 4-nitrobenzyl amine hydrochloride, and Et3N were suspended in toluene and stirred at 100° for 2.5 h to give Et [2-[N-(4-nitrobenzyl)carbamoyl]phenylamino]acetate, which was cyclocondensed with 1,1'-carbonyldiimidazole at 130° for 2 h to give I (R1 = 4-nitrobenzyl, R2 = CH2CO2Et, R3 = R4 = H), diazotized with NaNO2 in HBr/aqueous acetone at 5°, and coupled with Et acrylate in the presence of Cu2O at 30° to give I (R1 = Q, R2 = CH2CO2Et, R3 = R4 = H). The latter compound was cyclocondensed with thiourea in the presence of AcONa in ethanol under reflux for 6 h to give I (R1 = Q1, wherein Z = NH, R2 = CH2CO2Et, R3 = R4 = H), which was hydrolyzed in 2 N aqueous HCl under reflux to give I (R1 = Q1, wherein Z = O, R2 = CH2CO2Et, R3 = R4 = H) and I (R1 = Q1, wherein Z = O, R2 = CH2CO2H, R3 = R4 = H). I (R1 = Q2, R2 = CH2CO2H, R3 = 7-Cl, R4 = H) and I (R1 = Q3, R2 = CH2CO2H, R3 = R4 = H) in vitro showed IC50 of 3.34 × 10⁻⁸ and 2.13 × 10⁻⁶ M, resp., against aldose reductase, and at 100 mg/kg/day p.o. for 2 days in vivo lowered blood sugar by 13 and 36%, resp.
 IT 180632-11-5P 180632-13-7P 180632-19-3P
 180632-21-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of dioxotetrahydroquinazoline derivs. having blood sugar-lowering and aldose reductase-inhibiting activity for treating diabetes complications)
 RN 180632-11-5 HCAPLUS
 CN 3(2H)-Quinazolinoneacetic acid, 1-[[4-[(2,4-dioxo-5-

L4 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
thiazolidinyl)methyl]phenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 180632-13-7 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[[3-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 180632-19-3 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[[[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]sulfonyl]amino]phenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 180632-21-7 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[[[4-[(2,4-dioxo-5-thiazolidinyl)methyl]phenyl]sulfonyl]amino]phenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 180632-52-4P 180632-53-5P 180632-54-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of dioxotetrahydroquinazoline derivs. having blood sugar-lowering and aldose reductase-inhibiting activity for treating diabetes complications)

RN 180632-52-4 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1,4-dihydro-1-[(3-nitrophenyl)methyl]-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 180632-53-5 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[(3-aminophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 180632-54-6 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[[[3-(2-bromo-3-ethoxy-3-oxopropyl)phenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 14 HCAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1995:358755 HCAPLUS
 DOCUMENT NUMBER: 122:133211
 TITLE: Preparation of quinazoline, quinoline, and benzoxazine derivatives as ACAT inhibitors
 INVENTOR(S): Natsukari, Hideaki; Sugiyama, Yasuo; Morimoto, Shinji
 PATENT ASSIGNEE(S): Takeda Chemical Industries Ltd, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 26 pp.
 CODEN: JQKXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06263736	A2	19940920	JP 1994-2273	19940114
JP 3524133	B2	20040510		


PRIORITY APPLN. INFO.: JP 1993-5390 A 19930114
 OTHER SOURCE(S): MARPAT 122:133211
 GI For diagram(s), see printed CA issue.
 AB The title compds. I [ring A = (un)substituted benzene ring; ring B = (un)substituted aromatic ring; W = CO, CS, etc.; Y = CH, N, or WY = C:CH; X = CH₂, O, etc.; Z = NH, CH₂, etc.] dotted line indicates single bond or double bond; proviso are given; R = H, etc.), useful as ACAT (acyl-Co-A:cholesterol acyltransferase) inhibitors, are prepared 6-chloro-N-(2,6-diethoxyphenyl)-1,4-dihydro-2-oxo-1-phenylmethyl-3(2H)-quinazolineacetamide in vitro at 10⁻⁶ M gave 98.3% inhibition of ACAT. The inhibiting activities of 22 compds. of this invention against ACAT are given in a table of this document.
 IT 160974-66-3
 RL: RCT (Reactant); RACT (Reactant or reagent) (preparation of quinazoline, quinoline, and benzoxazine derivs. as ACAT inhibitors)
 RN 160974-66-3 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 7-chloro-1,4-dihydro-2,4-dioxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1991:559174 HCAPLUS
 DOCUMENT NUMBER: 115:159174
 TITLE: Preparation of quinazoline-3-alkanoates as platelet aggregation and aldose reductase inhibitors
 INVENTOR(S): Fujimori, Shizuyoshi; Ohnata, Michiro; Hirata, Yoshihiro; Murakami, Koji
 PATENT ASSIGNEE(S): Kyorin Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9109024	A1	19910627	WO 1990-JP1600	19901210

W: AU, CA, HU, KR, US
 BW: BE, CH, DE, ES, FR, GB, IT, NL, SE
 JP 03181469 A2 19910807 JP 1989-321097 19891211
 JP 07047582 B4 19950524
 CA 2046603 AA 19910612 CA 1990-2046603 19901210
 AU 9168905 A1 19910718 AU 1991-68905 19901210
 AU 640194 B2 19930819
 EP 456835 A1 19911121 EP 1991-900052 19901210
 EP 456835 B1 19960515
 R: BE, CH, DE, ES, FR, GB, IT, LI, NL, SE
 HU 58304 A2 19920228 HU 1991-2399 19901210
 HU 207999 B 19930728
 ES 2087991 T3 19960801 ES 1991-900052 19901210
 ES 5234928 A 19930810 US 1991-721610 19910717
 PRIORITY APPLN. INFO.: WO 1990-JP1600 A 19901210
 OTHER SOURCE(S): MARPAT 115:159174
 GI




AB The title compds. [I: R = H, carboxy-protective group; R1 = alkyl, alkenyl, alkynyl, alkoxy, alkylthio, halo, (substituted) Ph, heterocyclyl, or benzoyl, naphthyl, cycloalkyl; R2, R3 = H, halo, alkyl, alkoxy, (substituted) aralkyl, NO₂, imidazolyl, imidazolylmethyl, NR₄R₅; R4, R5 = H, alkyl or NR₄R₅ = 5- or 6-membered heterocyclyl optionally containing other heteroatom(s); X = CO, C(S), (alkyl-substituted) CH₂; A = alkylene, alkenylene; n = 1-3], useful for treatment of thrombosis, heart diseases, or diabetes complications, are prepared. Thus, condensation of H₂NCH₂CO₂Et.HCl with 6-chloro-2H-3,1-benzoxazine-2,4(1H)-dione in dioxane

L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 contg. Et₃N and cyclocondensation of the resulting 2,5-(H₂N)ClC₆H₃CONHCH₂CO₂Et with N,N'-carbonyldiimidazole in dioxane at 150° gave Et 6-chloro-1,4-dihydro-2,4-dioxo-3(2H)-quinazolineacetate which was alkylated with 2-ClC₆H₄CH₂Cl in the presence of NaH in DMF at 70° to give Et 6-chloro-1-(4-chlorophenyl)methyl-1,4-dihydro-2,4-dioxo-3(2H)-quinazolineacetate. A total of 196 I were prep'd. and in vitro inhibited aldose reductase with IC₅₀ of 10⁻⁷ - 10⁻⁸ M and arachidonic acid-induced rabbit's platelet aggregation with IC₅₀ of 10⁻⁵ - 10⁻⁷ M.
 IT 133166-46-8P 133166-48-0P 133166-49-1P
 133166-50-4P 133166-53-7P 133166-57-1P
 133166-58-2P 133166-59-3P 133166-60-6P
 133166-64-0P 136147-80-3P 136147-81-4P
 136147-82-5P 136147-84-7P 136147-85-8P
 136147-87-0P 136147-88-1P 136147-89-2P
 136147-90-5P 136147-91-6P 136147-93-8P
 136147-94-9P 136147-95-0P 136147-96-1P
 136147-97-2P 136147-98-3P 136147-99-4P
 136148-00-0P 136148-01-1P 136148-02-2P
 136148-03-3P 136148-04-4P 136148-05-5P
 136148-06-6P 136148-07-7P 136148-08-8P
 136148-09-9P 136148-10-2P 136148-11-3P
 136148-12-4P 136148-13-5P 136148-15-7P
 136148-16-8P 136148-17-9P 136148-18-0P
 136148-19-1P 136148-20-4P 136148-21-5P
 136148-22-6P 136148-23-7P 136148-24-8P
 136148-25-9P 136148-27-1P 136148-29-3P
 136148-31-7P 136148-32-8P 136148-33-9P
 136148-34-0P 136148-37-3P 136148-38-4P
 136148-40-8P 136148-41-9P 136148-42-0P
 136148-43-1P 136148-44-2P 136148-45-3P
 136148-49-7P 136148-50-0P 136148-53-3P
 136148-54-4P 136148-55-5P 136148-69-1P
 136148-74-8P 136148-75-9P 136148-76-0P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as aldose reductase and platelet aggregation inhibitor)
 RN 133166-46-8 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 6-bromo-1-[(4-bromo-2-fluorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 133166-48-0 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 1-[(4-bromo-2-fluorophenyl)methyl]-7-chloro-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 133166-49-1 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 1-[(4-bromo-2-fluorophenyl)methyl]-6-chloro-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 133166-50-4 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 1-[(4-bromo-2-fluorophenyl)methyl]-5-chloro-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




10/ 750,326

L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 133166-53-7 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 1-[(4-bromo-2-fluorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 133166-57-1 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 6-bromo-1-[(3,4-dichlorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 133166-58-2 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 6-chloro-1-[(3,4-dichlorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 133166-59-3 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 1-[(3,4-dichlorophenyl)methyl]-1,4-dihydro-6-methoxy-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 133166-60-6 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 1-[(3,4-dichlorophenyl)methyl]-1,4-dihydro-6-methyl-2,4-dioxo- (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 133166-64-0 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 1-[(4-bromo-2-fluorophenyl)methyl]-1,4-dihydro-6-nitro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136147-80-3 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 6-chloro-1-[(4-fluorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136147-81-4 HCAPLUS


L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 3(2H)-Quinazolineacetic acid, 1-[(4-chlorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)



RN 136147-82-5 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 6-chloro-1-[(2,4-dichlorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136147-84-7 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 6-chloro-1-[(3-fluorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




10/ 750,326

L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 136147-85-8 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 6-chloro-1-[(2-chlorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136147-87-0 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 6-chloro-1-[(3-chlorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136147-88-1 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[(4-bromophenyl)methyl]-6-chloro-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 136147-89-2 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 6-chloro-1-[(4-methoxyphenyl)methyl]-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136147-90-5 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[(2,4-dichlorophenyl)methyl]-1,4-dihydro-6-methoxy-2,4-dioxo- (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 136147-91-6 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 6-chloro-1,4-dihydro-1-(1-naphthalenylmethyl)-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136147-93-8 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 6-chloro-1,4-dihydro-1-[(4-nitrophenyl)methyl]-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136147-94-9 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 6-chloro-1-[(2,6-dichlorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 136147-95-0 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[(2,4-dichlorophenyl)methyl]-1,4-dihydro-6-methyl-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136147-96-1 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[(2,4-dichlorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136147-97-2 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[(2,4-dichlorophenyl)methyl]-6-fluoro-1,4-


L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)



RN 136147-98-3 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 1-[(3,4-dichlorophenyl)methyl]-6-fluoro-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136147-99-4 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 6-chloro-1,4-dihydro-2,4-dioxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 136148-00-0 HCAPLUS


L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136148-04-4 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 1-[(2,4-difluorophenyl)methyl]-6-fluoro-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136148-05-5 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 7-chloro-1-[(2,4-dichlorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 3(2H)-Quinazolineacetic acid, 6-chloro-1-(cyclohexylmethyl)-1,4-dihydro-2,4-dioxo-1-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 136148-01-1 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 6-chloro-1-(cyclohexylmethyl)-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136148-02-2 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 1-[(3,4-dichlorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136148-03-3 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 6-chloro-1-[(2,4-difluorophenyl)methyl]-1,4-

L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 136148-06-6 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 1-[(2,4-dichlorophenyl)methyl]-1,4-dihydro-6,7-dimethoxy-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136148-07-7 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 6-chloro-1,4-dihydro-2,4-dioxo-1-[(4-(trifluoromethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 136148-08-8 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 6-chloro-1-[(3,4-difluorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136148-09-9 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 7-chloro-1-[(3,4-dichlorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136148-10-2 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 6-chloro-1,4-dihydro-2,4-dioxo-1-[[3-(trifluoromethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 136148-13-5 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1,4-dihydro-2,4-dioxo-1-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)




RN 136148-15-7 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[(3,4-dichlorophenyl)methyl]-1,4-dihydro-6,7-dimethoxy-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136148-16-8 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 6-bromo-1-[(2,4-dichlorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136148-11-3 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 6-chloro-1,4-dihydro-1-[(4-methylphenyl)methyl]-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136148-12-4 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[2-(4-chlorophenyl)-2-oxoethyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)



RN 136148-17-9 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[(3,4-difluorophenyl)methyl]-1,4-dihydro-6-methyl-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136148-18-0 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[(3,4-difluorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136148-19-1 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 6-chloro-1,4-dihydro-2,4-dioxo-1-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)

10/ 750,326


L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN propenyl)- (9CI) (CA INDEX NAME)



RN 136148-20-4 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 6-chloro-1-[(3,4-dimethylphenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136148-21-5 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[(3,4-difluorophenyl)methyl]-6-fluoro-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136148-22-6 HCAPLUS


L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 136148-25-9 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 6-chloro-1,4-dihydro-2,4-dioxo-1-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 136148-27-1 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[(3,4-dimethoxyphenyl)methyl]-1,4-dihydro-6,7-dimethoxy-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136148-29-3 HCAPLUS

L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 3(2H)-Quinazolineacetic acid, 5-chloro-1-[(3,4-dichlorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136148-23-7 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 5-chloro-1-[(3,4-difluorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136148-24-8 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 6-chloro-1-[(3,4-dimethoxyphenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 3(2H)-Quinazolineacetic acid, 1-[(3,4-dichlorophenyl)methyl]-6-ethyl-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136148-31-7 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[(4-bromo-2-fluorophenyl)methyl]-6-ethyl-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136148-32-8 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[(4-bromo-2-fluorophenyl)methyl]-1,4-dihydro-6,7-dimethoxy-2,4-dioxo- (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 136148-33-9 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[(4-bromo-2-fluorophenyl)methyl]-6-fluoro-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136148-34-0 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[(4-bromo-2-fluorophenyl)methyl]-1,4-dihydro-6-methyl-2,4-dioxo- (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 136148-37-3 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 6-[(2,4-dichlorophenyl)methoxy]-1-[(2,4-dichlorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136148-38-4 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[(3,4-dichlorophenyl)methyl]-6-(dimethylamino)-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 136148-40-8 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[(4-bromo-2-fluorophenyl)methyl]-1,4-dihydro-2,4-dioxo-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 136148-41-9 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[(4-bromo-2-fluorophenyl)methyl]-6-(dimethylamino)-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136148-42-0 HCAPLUS


L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 136148-43-1 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[(4-bromo-2-fluorophenyl)methyl]-1,4-dihydro-6-methoxy-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136148-44-2 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[(3,4-dichlorophenyl)methyl]-1,4-dihydro-2,4-dioxo-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 136148-45-3 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[(3,4-dichlorophenyl)methyl]-1,4-dihydro-6-(methylthio)-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136148-49-7 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 6,8-dichloro-1-[(3,4-dichlorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136148-50-0 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 6-chloro-1,4-dihydro-1-[(4-(2-hydroxyethenyl)phenyl)methyl]-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136148-53-3 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[(4-chlorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136148-54-4 HCAPLUS
CN 3(2H)-Quinazolinepropanoic acid, 1-[(2,4-dichlorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136148-55-5 HCAPLUS
CN 3(2H)-Quinazolinebutanoic acid, 1-[(2,4-dichlorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)



RN 136148-69-1 HCAPLUS




RN 136148-74-8 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[(2,4-dichlorophenyl)methyl]-6-fluoro-1,4-dihydro-7-(1H-imidazol-1-yl)-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 136148-75-9 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 6-fluoro-1,4-dihydro-7-(1H-imidazol-1-yl)-2,4-dioxo-1-[(4-(trifluoromethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 136148-76-0 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 1-[(3,4-dichlorophenyl)methyl]-6-fluoro-1,4-dihydro-7-(1H-imidazol-1-yl)-2,4-dioxo- (9CI) (CA INDEX NAME)




L4 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 133166-48-0 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 1-[(4-bromo-2-fluorophenyl)methyl]-7-chloro-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 133166-49-1 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 1-[(4-bromo-2-fluorophenyl)methyl]-6-chloro-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)



RN 133166-50-4 HCAPLUS


L4 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1991:247224 HCAPLUS
 DOCUMENT NUMBER: 114:247224
 TITLE: Quinazolineacetic acids and related analogs as aldose reductase inhibitors
 AUTHOR(S): Malamas, Michael S.; Millen, Jane
 CORPORATE SOURCE: Wyeth-Ayerst Res., Princeton, NJ, 08543-8000, USA
 SOURCE: Journal of Medicinal Chemistry (1991), 34(4), 1492-503
 CODEN: JMCMAR ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB A variety of 2,4-dioxoquinazolineacetic acids (e.g., I) were synthesized as hybrids of the known aldose reductase inhibitors alrestatin, ICI-105,552, and ICI-128,436 and evaluated for their ability to inhibit partially purified bovine lens aldose reductase (in vitro) and their effectiveness to decrease galactitol accumulation in the 4-day galactosamic rat model (in vivo). In support of SAR studies, related analogs pyrimidinediones, dihydroquinazolones, and indazolidinones were synthesized and tested in the in vitro and in vivo assays. All prepared compounds have shown a high level of in vitro activity (IC50 approx. 10⁻⁶ to 4 × 10⁻⁸ M). However, only the 2,4-quinazolinodione analog, with similar N-aralkyl substitution exhibited good oral potency. The remaining compounds were either inactive or had only a marginal in vivo activity. The structure-activity data support the presence of a secondary hydrophobic pocket in the vicinity of the primary lipophilic region of the enzyme.

IT 133166-46-8P 133166-48-OP 133166-49-1P
 133166-50-4P 133166-53-7P 133166-54-8P
 133166-55-9P 133166-56-OP 133166-57-1P
 133166-58-2P 133166-59-3P 133166-60-6P
 133166-61-7P 133166-64-OP 133166-65-1P
 133166-67-3P 133166-68-4P 133166-69-5P
 133166-70-8P 133166-71-9P 133166-72-OP
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and aldose reductase inhibition activity of)
 RN 133166-46-8 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 6-bromo-1-[(4-bromo-2-fluorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 3(2H)-Quinazolineacetic acid, 1-[(4-bromo-2-fluorophenyl)methyl]-5-chloro-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 133166-53-7 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 1-[(4-bromo-2-fluorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 133166-54-8 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 1-[(4-bromo-2-fluorophenyl)methyl]-8-fluoro-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)

10/ 750,326


L4 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 133166-55-9 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[(4-bromo-2-fluorophenyl)methyl]-1,4-dihydro-6-iodo-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 133166-56-0 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 6-bromo-1,4-dihydro-2,4-dioxo-1-(1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 133166-57-1 HCAPLUS


L4 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 133166-60-6 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[(3,4-dichlorophenyl)methyl]-1,4-dihydro-6-methoxy-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 133166-61-7 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 6-bromo-1-[(3,4-difluorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 133166-64-0 HCAPLUS

L4 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 3(2H)-Quinazolineacetic acid, 6-bromo-1-[(3,4-dichlorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 133166-58-2 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 6-chloro-1-[(3,4-dichlorophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 133166-59-3 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[(3,4-dichlorophenyl)methyl]-1,4-dihydro-6-methoxy-2,4-dioxo- (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 3(2H)-Quinazolineacetic acid, 1-[(4-bromo-2-fluorophenyl)methyl]-1,4-dihydro-6-nitro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 133166-65-1 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-[(4-bromo-2-fluorophenyl)methyl]-1,4-dihydro-6-nitro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 133166-67-3 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 6-bromo-1-[(3-bromo-4-methoxyphenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 133166-68-4 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 6-bromo-1,4-dihydro-2,4-dioxo-1-[(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 133166-69-5 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 6-bromo-1,4-dihydro-2,4-dioxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 133166-70-8 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 6-bromo-1,4-dihydro-1-[(4-methoxyphenyl)methyl]-2,4-dioxo- (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 133166-71-9 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 6-bromo-1,4-dihydro-2,4-dioxo-1-[(4-(trifluoromethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 133166-72-0 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 6-bromo-1-[(4-bromophenyl)methyl]-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN


ACCESSION NUMBER: 1990:478326 HCAPLUS
 DOCUMENT NUMBER: 113:78326
 TITLE: Aldose reductase inhibition by 2,4-dioxo and thioxo derivatives of 1,2,3,4-tetrahydroquinazoline
 AUTHOR(S): Billon, Florence; Delchambre, Chantal; Cloarec, Alim; Sartori, Eric; Teulon, Jean Marie
 CORPORATE SOURCE: CARPIBEM Lab., Rueil-Malmaison, 92506, Fr.
 SOURCE: European Journal of Medicinal Chemistry (1990), 25(2), 121-6
 CODEN: EJMCA5; ISSN: 0223-5234
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 113:78326
 GI



AB Original [(2,4-dioxo-1,2,3,4-tetrahydroquinazolin-1-yl) acetic acids and their thioxo derivs. (e.g., I X=O, S: R=H, R1 = OH, MeO) were prepared from isatoic anhydride and examined for their ability to inhibit aldose reductase in vitro and in vivo. Most were active in vitro on rat lens aldose reductase in the 10⁻⁷ M range. I (X = O, R = F, R1 = Br) was a good inhibitor of galactitol accumulation in sciatic nerves in hypergalactosemic rats and prevented cataract formation.

IT 128650-89-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (Preparation and aldose reductase-inhibiting activity of)

RN 128650-89-5 HCAPLUS
 CN 3(2H)-Quinazolineacetic acid, 1,4-dihydro-2,4-dioxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 13 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1988:56027 HCAPLUS
 DOCUMENT NUMBER: 108:56027
 TITLE: Quinazolinecarboxylic acids. Part X. Synthesis of 1-methyl-2,4-dioxoquinazolin-3-yl-acetic acid, 2,4-dioxoquinazolin-1-yl-acetic acids, 2,4-dioxo-1,3-quinazolinodiacetic acids and their esters

AUTHOR(S): Suesse, Manfred; John, Siegfried
 CORPORATE SOURCE: Inst. Biochem. Pflanz., Dtsch. Akad. Wiss., Halle/Saale, DDR-4050, Ger. Dem. Rep.
 SOURCE: Monatshefte fuer Chemie (1987), 118(1), 71-9
 CODEN: MOCHB7; ISSN: 0026-9247


DOCUMENT TYPE: Journal
 LANGUAGE: German
 OTHER SOURCE(S): CASREACT 108:56027
 GI




AB 2,4-Dioxoquinazolin-1-yl-acetic acid esters I (R = H, Br, Cl; R1 = Me) were prepared by the reaction of either 3,1-benzoxazine-2,4-diones II with urea in the melt or in solution or of the substituted anthranilic acid ester with potassium cyanate in acid solution. The anthranilamides III with trichloromethyl chloroformate (diphosgene) also gave I. Alkaline hydrolysis of I (R1 = Me) affords I (R = H). 2,4-Dioxo-1,3-quinazolinodiacetic acids were synthesized from II and glycine ester. Quinazoline-2,4-dione with Et bromoacetate yielded IV (R2 = CO2Et) and with chloroacetonitrile IV (R2 = cyano). 1-Methyl-3,1-benzoxazine-2,4-dione was transformed under similar conditions into 1-methyl-2,4-dioxoquinazolin-3-yl-acetic acid.

IT 105407-94-1P 112342-57-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and neutralization of)
 RN 105407-94-1 HCAPLUS
 CN 1,3(2H,4H)-Quinazolinodiacetic acid, 6-chloro-2,4-dioxo-, dipotassium salt (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L4 ANSWER 13 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● 2 K

RN 112342-57-1 HCAPLUS
 CN 1,3(2H,4H)-Quinazolinodiacetic acid, 2,4-dioxo-, dipotassium salt (9CI) (CA INDEX NAME)



● 2 K

IT 105407-95-2P 112342-48-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 105407-95-2 HCAPLUS
 CN 1,3(2H,4H)-Quinazolinodiacetic acid, 6-chloro-2,4-dioxo- (9CI) (CA INDEX NAME)




RN 112342-48-0 HCAPLUS
 CN 1,3(2H,4H)-Quinazolinodiacetic acid, 2,4-dioxo- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1986:626633 HCAPLUS
 DOCUMENT NUMBER: 105:226633
 TITLE: 1,2,3,4-Tetrahydroquinazoline-2,4-dioneacetates
 INVENTOR(S): Suesse, Manfred; John, Siegfried
 PATENT ASSIGNEE(S): Akademie der Wissenschaften der DDR, Ger. Dem. Rep.
 SOURCE: Ger. (East), 12 pp.
 CODEN: GEXXAS
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DD 232702	A1	19860205	DD 1982-243374	19820920
PRIORITY APPLN. INFO.:			DD 1982-243374	19820920
OTHER SOURCE(S):		CASREACT 105:226633		

GI



AB Title compds. I [R = halo, NO2, cyano, alkyl, alkoxy; R1 = H, alkali metal, alkyl; R2 = H, (substituted) alkyl, aryl, heterocycle; n = 0-4], potentially useful in agriculture or medicine (no data), are prepared from isatoic anhydrides II and amines or ureas, or from isatoates. Thus, II (n = 0, R1 = Et) reacted sequentially with Et glycinate and phosgene to give 514 I (n = 0, R1 = Et, R2 = CH2CO2Et).

IT 105407-94-1P 105407-95-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 105407-94-1 HCAPLUS
 CN 1,3(2H,4H)-Quinazolinodiacetic acid, 6-chloro-2,4-dioxo-, dipotassium salt (9CI) (CA INDEX NAME)



● 2 K

RN 105407-95-2 HCAPLUS
 CN 1,3(2H,4H)-Quinazolinodiacetic acid, 6-chloro-2,4-dioxo- (9CI) (CA INDEX NAME)

10/ 750,326

14 ANSWER 14 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
NAME)

